The Chackerian laboratory is interested in vaccine development; particularly the use of virus particles as platforms for antigen display. It has long been recognized that highly dense repetitive antigens such as virus particles induce strong immune responses. However, more recent studies from Dr. Chackerian's laboratory has demonstrated that antigens that are normally poorly immunogenic can be made highly immunogenic by displaying them in a multivalent, repetitive format on the surface of virus particles; essentially using viruses as platforms for vaccines. Dr. Chackerian has shown that this ability to enhance immunogenicity does not only apply to epitopes derived from traditional targets, such as pathogens, but also to self-antigens which are normally subject to the mechanisms of B cell tolerance. Using virus-like particles derived from RNA bacteriophage, he has been collaborating with Dr. David Peabody (also a member of MGM) to develop and implement a system that allows vaccines to be rapidly identified by affinity selection. He also has projects to develop novel vaccines targeting Human Papillomavirus, Chlamydia, Malaria, HIV, and high cholesterol. More information on HPV research at UNM is here.
Dr. Chackerian received his BA at the University of California, Berkeley and his PhD from the University of Washington. He then trained in John Schiller's laboratory at the National Cancer Institute. In 2004 he joined the Department of Molecular Genetics and Microbiology at the University of New Mexico. He is a member of the UNM Cancer Center and the Center for Infectious Disease and Immunity. He also serves as co-block chair for the Foundations of Medical Sciences block for 1st year medical students.
Chackerian Lab (September 2013)
Selected PublicationsLink to PubMed
Frietze, K., Pascale, J.M., Moreno, B., Chackerian, B., and D.S. Peabody (2017). Pathogen-specific deep sequence-coupled biopanning: A method for surveying human antibody responses. PLoS One 2017 Feb 2;12(2):e0171511. doi: 10.1371/journal.pone.0171511.
Chackerian, B.* and A.T. Remaley (2016). Vaccine strategies for lowering LDL by immunization against PCSK9. Current Opinion in Lipidology. 2016 Aug;27(4):345-50.
Saboo, S., Tumban, E., Peabody, J., Wafula, D., Peabody, D.S., Chackerian, B., and P. Muttil (2016). An optimized formulation of a thermostable spray-dried virus-like particle vaccine against human papillomavirus. Molecular Pharmaceutics. 2016 May 2;13(5):1646-55.
Frietze, K.M., Roden, R.B.S., Lee, J-H., Shi, Y., Peabody, D.S., and B. Chackerian* (2016). Identification of anti-CA125 antibody responses in ovarian cancer patients by a novel deep sequence-couple biopanning platform. Cancer Immunology Research. 2016 Feb;4(2):157-64.
Frietze, K.M., Peabody, D.S., and B. Chackerian* (2016). Engineering virus-like particles as vaccine platforms. Current Opinion in Virology. 2016 Jun 18: 44-49.
Chackerian, B.* and K.M. Frietze (2016). Moving towards a new class of vaccines for non-infectious chronic diseases. Expert Review of Vaccines. 2016 Feb 26. [Epub ahead of print]
Jiang, R.T., Schellenbacher, C., Chackerian, B., and R.B.S. Roden (2016) Progress and prospects for L2-based human papillomavirus vaccines. Expert Review of Vaccines. 2016 Mar 10:1-10.
Caldeira, J., Bustos, J., Peabody, J., Chackerian, B., and D. S. Peabody (2015). A Contraceptive Vaccine on a Virus-like Particle Platform. PLoS One. 2015 Oct 30;10(10):e0141407.
Crossey, E., Amar, M.J.A., Sampson, M., Peabody, J., Schiller, J.T., Chackerian, B.*, and A.T. Remaley (2015). A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine. 2015 Oct 26;33(43):5747-55. doi: 10.1016/j.vaccine.2015.09.044. Epub 2015 Sep 26
Crossey, E., Frietze, K., Narum, D. L., Peabody, D. S., and B. Chackerian* (2015). Identification of an Immunogenic Mimic of a Conserved Epitope on the Plasmodium falciparum Blood Stage Antigen AMA1 Using Virus-Like Particle (VLP) Peptide Display. PLoS One. 2015 Jul 6;10(7):e0132560.
Tumban, E., Muttil, P., Escobar, C. A. A., Peabody, J., Wafula, D., Peabody, D. S., and B. Chackerian* (2015). Preclinical Refinements of a Broadly Protective VLP-based HPV Vaccine Targeting the Minor Capsid Protein, L2. Vaccine. Jun 26;33(29):3346-53. Epub 2015 May 21.
O’Rourke, J., Peabody, D.S., and B. Chackerian* (2015). Affinity Selection of Epitope-based Vaccines using a Bacteriophage Virus-like Particle Platform. Current Opinion in Virology. 2015 Mar 26;11:76-82.
O’Rourke, J. P., Daly, S. M., Peabody, D. S., Chackerian, B., and P. R. Hall (2014). Development of a Mimotope Vaccine Targeting the Staphylococcus aureus Quorum Sensing Pathway. PLoS One. 2014 Nov 7;9(11):e111198.
Ord, R. L., Caldeira, J. C., Rodriguez, M., Noe, A., Chackerian, B., Peabody, D. S., Gutierrez, G., and C. A. Lobo (2014). A Malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein. Malaria Journal. 2014 Aug 18;13(1):326. [Epub ahead of print]
Tyler, M., Tumban, E., Dziduszko, A, Ozbun, M. A., Peabody, D. S., and B. Chackerian* (2014). Immunization with a consensus epitope from Human Papillomavirus L2 induces antibodies that are broadly neutralizing. Vaccine. 2014 Jul 23;32(34):4267-74. doi: 10.1016/j.vaccine.2014.06.054. Epub 2014 Jun 21.
Schiller, J.T. and B. Chackerian (2014). Why HIV Virions Have Low Numbers of Envelope Spikes; Implications for Vaccine Development. PLoS Pathogens. August 7, 2014. DOI: 10.1371/journal.ppat.1004254.
Tyler, M., Tumban, E., Peabody, D. S., and B. Chackerian* (2014). The use of hybrid Virus-like Particles to enhance the immunogenicity of a broadly protective HPV vaccine. Biotechnology and Bioengineering. 2014 Jun 11. doi: 10.1002/bit.25311. [Epub ahead of print].
Van Rompay, K.K.A., Hunter, Z., Jayashankar, K., Peabody, J., Montefiori, D., LaBranche, C.C., Keele, B.F., Jensen, K., Abel, K., and B. Chackerian* (2014). A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with SIVmac251. Journal of Virology. Feb;88(4):2011-24. Epub 2013 Dec 4.
McCarthy, D.P., Hunter, Z.N., Chackerian, B., Shea, L.D., and Miller, S.D. (2014). Targeted immunomodulation using antigen-conjugated nanoparticles.Wiley Interdiscip Rev Nanomed Nanobiotechnol. Epub 2014 Mar 10.
Tyler, M.R., Tumban, E., and B. Chackerian* (2014). Second-Generation Prophylactic HPV Vaccines: Successes and Challenges. Expert Reviews of Vaccines. Feb;13(2):247-55. Epub 2013 Dec 18
Tumban, E., Peabody, J., Peabody, D.S., and B. Chackerian* (2013). A Universal Virus-Like Particle-based Vaccine for Human Papillomavirus: Longevity of Protection and Role of Endogenous and Exogenous Adjuvants. Vaccine Sept 23;31(41):4647-4654. Epub 2013 Aug 9.
Tumban, E., Peabody, J., Tyler, M.R., Peabody, D.S., and B. Chackerian* (2012). VLPs Displaying a Single L2 epitope Induce Broadly Cross-neutralizing Antibodies Against Human Papillomavirus. PLoS One 7(11): e49751. doi:10.1371/journal.pone.0049751
Cuburu, N. and B. Chackerian (2011). Genital Delivery of Virus-like Particle and Pseudovirus Based Vaccines. Expert Reviews of Vaccines 10(9), 1245-48.
Tumban, E., Peabody, J., Peabody, D.S., and B. Chackerian (2011). A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2. PLoS One 2011; 6(8): e23310. Epub 2011 Aug 17.
Hunter, Z., Tumban, E., Dziduszko, A., and B. Chackerian (2011). Aerosol delivery of Virus-like particles to the genital tract induces local and systemic antibody responses. Vaccine. May 5. Jun 20;29(28):4584-92. Epub 2011 May 5.
Chackerian, B., Caldeira, J. D., Peabody, J., and D. S. Peabody (2011). Peptide Epitope Identification by Affinity Selection on Bacteriophage MS2 Virus-like Particles. Journal of Molecular Biology. Jun 3;409(2):225-37. Epub 2011 Apr 9.
B. Chackerian (2010). Virus-like Particle Vaccines for Alzheimer's Disease.Human Vaccines. 2010 Nov;6(11):926-30. Epub 2010 Nov 1.
Caldeira, J.D., Medford, A., Kines, R.C., Lino, C.A., Schiller, J.T., Chackerian, B., and D.S. Peabody (2010). Immunogenic Display of Diverse Peptides, Including a Broadly Cross-Type Neutralizing Human Papillomavirus L2 epitope, on Virus-like Particles of the RNA Bacteriophage PP7. Vaccine, 28 (27), 4384-4393. Epub 2010 Apr 29.
Li, Q.Y. Gordon, M. N., Chackerian, B., Alamed, J., Ugen, K. E., and D. Morgan (2010). Virus-like Peptide Vaccines Against Aß N-terminal or C-terminal Domains Reduce Amyloid Deposition in APP Transgenic Mice without Addition of Adjuvant. Journal of Neuroimmune Pharmacology, 5 (1), 133-42.
Hunter, Z., Smyth, H. D., Durfee, P., and B. Chackerian (2009). Induction of mucosal and systemic antibody responses by aerosol delivery and intramuscular immunization of Virus-like Particle based vaccines targeting CCR5. Vaccine, 28 (2), 403-414. Epub 2009 Oct 20.
Peabody, D. S., Manifold-Wheeler, B., Medford, A., Jordan, S. K. Caldeira, J., and B. Chackerian (2008). Immunogenic Display of Diverse Peptides on Virus-Like Particles of RNA Phage MS2. Journal of Molecular Biology, 380, 252-263.
Chackerian, B. Durfee, M. R., and J. T. Schiller (2008). Virus-like Display of a Neo-self Antigen Reverses B cell Anergy in a B cell Receptor Transgenic Mouse Model. Journal of Immunology, 180 (9), 5816-5825.
B. Chackerian (2007). Virus-like Particles: Flexible Platforms for Vaccine Development. Expert Reviews of Vaccines 6 (3), 381-390.
Chackerian, B., Rangel, M., Hunter, Z., and D. S. Peabody (2006). Virus and virus-like particle based immunogens for Alzheimer's disease induce antibody responses against Amyloid-Beta without concomitant T cell responses. Vaccine 24 (37-39), 6321-6331.
Chackerian, B., Briglio, L., Albert, P. S., Lowy, D. R., and J. T. Schiller (2004). Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic Simian/Human Immunodeficiency Virus. Journal of Virology 78 (8), 4037-4047.
Li, Q., Cao, C., Chackerian, B., Schiller, J. T., Gordon, M., Ugen, K. E., and D. Morgan (2004). Overcoming Antigen Masking of Anti-Abeta Antibodies Reveals Breaking of B cell Tolerance in Abeta Immunized Amyloid Precursor Protein Transgenic Mice. BMC Neuroscience 5: 21 (8 June 2004).
Chackerian, B., Lenz, P., Lowy, D. R., and J. T. Schiller (2002). Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. Journal of Immunology 169 (11), 6120-6126.
Chackerian, B., Lowy, D. R., and J. T. Schiller (2001). Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. Journal of Clinical Investigation 108 (3), 415-423.
Chackerian, B., Lowy, D. R., and J. T. Schiller (1999). Induction of auto-antibodies to mouse CCR5 with recombinant papillomavirus particles. Proceedings of the National Academy of Sciences USA 96 (5), 2373-2378.